Pierre Fabre F60089IV101 VERT-002

{ "short_title": "Pierre Fabre F60089IV101 VERT-002", "data_mode": "900", "data_mode_number": "000002486", "official_title": "A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "first", "ctgov_number": "NCT06669117", "eudract_number": null, "general_contact_email": "ectu@ukdd.de", "general_contact_phone": "+49 351-4587566", "hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke", "description_laie_de": "Ziel dieser klinischen Studie ist es, die Sicherheit und Aktivit\u00e4t von VERT-002 (PFL-002) sowie die optimale sichere Dosis bei Teilnehmern mit soliden Tumoren, einschlie\u00dflich nicht-kleinzelligem Lungenkrebs, zu untersuchen.", "description_laie_en": "The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.", "description_expert_de": "Ziel dieser klinischen Studie ist es, die Sicherheit und Aktivit\u00e4t von VERT-002 (PFL-002) sowie die optimale sichere Dosis bei Teilnehmern mit soliden Tumoren, einschlie\u00dflich nicht-kleinzelligem Lungenkrebs, zu untersuchen.", "description_expert_en": "The goal of this clinical trial is to investigate the safety, the activity of VERT-002(PFL-002), and the optimal safe dose to be used, in participants with solid tumorsincluding non-small cell lung cancer.", "rechtsgrundlage_value": "AMG", "phase_amg_value": "I_II", "main_cat_id": 10, "sub_cat_id": 50 }